Prof. Kalra (Karnal, India)

Trajenta is suitable for a broad range of patients with type 2 diabetes.
Whenever I need to prescribe a DPP4 inhibitor, I consider Trajenta because I am confident about its established efficacy, the demonstrated cardiovascular and kidney safety profile, the unique convenience of always one dose, once daily, regardless of the patient’s age, kidney and liver function, weight or background therapy.
I would recommend Trajenta for a broad range of patients with type 2 diabetes whenever a DPP4 inhibitor is considered.